Skip to main navigation
logo
Careers
Contact Us
  • About Us
  • Technology
  • Pipeline
  • Products
    • DEXYCU
    • YUTIQ
  • Investors
    • Financial Information
      • Financials Overview
      • Stock Information
      • Analyst Coverage
      • Ownership Summary
      • Annual Reports
      • Earnings Releases
      • SEC Filings
    • Resources
      • Press Releases
      • Events & Presentations
      • Online Investor Kit
      • IR Contact
      • E-mail Alerts
    • Corporate Governance
      • Governance Overview
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • FAQs
    • ASX Delisting
    • Form 8937
  • News
Menu
  • About Us
  • Technology
  • Pipeline
  • Products
    • DEXYCU
    • YUTIQ
  • Investors
    • Financial Information
      • Financials Overview
      • Stock Information
      • Analyst Coverage
      • Ownership Summary
      • Annual Reports
      • Earnings Releases
      • SEC Filings
    • Resources
      • Press Releases
      • Events & Presentations
      • Online Investor Kit
      • IR Contact
      • E-mail Alerts
    • Corporate Governance
      • Governance Overview
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • FAQs
    • ASX Delisting
    • Form 8937
  • News
Menu
  • About Us
  • Technology
  • Pipeline
  • Products
    • DEXYCU
    • YUTIQ
  • Investors
    • Financial Information
      • Financials Overview
      • Stock Information
      • Analyst Coverage
      • Ownership Summary
      • Annual Reports
      • Earnings Releases
      • SEC Filings
    • Resources
      • Press Releases
      • Events & Presentations
      • Online Investor Kit
      • IR Contact
      • E-mail Alerts
    • Corporate Governance
      • Governance Overview
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • FAQs
    • ASX Delisting
    • Form 8937
  • News

ASX Delisting Information

  • Financial Information
    • Financials Overview
    • Stock Information
    • Analyst Coverage
    • Ownership Summary
    • Annual Reports
    • Earnings Releases
    • SEC Filings
  • Resources
    • Press Releases
    • Events & Presentations
    • Online Investor Kit
    • IR Contact
    • E-mail Alerts
  • Corporate Governance
    • Governance Overview
    • Management Team
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • FAQs
  • ASX Delisting
  • Form 8937
Title Type
EyePoint Extends Closing of Compulsory Sale Facility
EyePoint Extends Closing of Compulsory Sale Facility 30.5 KB
ASX Delisting - Notice of Revocation of Trust.
ASX Delisting - Notice of Revocation of Trust. 207 KB
Announcement of Approval to Delist From ASX and Letter to CDI Holders.
Announcement of Approval to Delist From ASX and Letter to CDI Holders. 2.7 MB
ASX Announcement - Suspension From Official Quotation
ASX Announcement - Suspension From Official Quotation 307.3 KB
pSivida Corp. Announces Plan to Delist From the Australian Securities Exchange
pSivida Corp. Announces Plan to Delist From the Australian Securities Exchange 78.8 KB
Delisting Letter and Timetable
Delisting Letter and Timetable 235.3 KB
Frequently Asked Questions
Frequently Asked Questions 202.4 KB
Form W-8 BEN
Form W-8 BEN 222 KB
  • Print Page
  • Printed Materials
  • Email Alerts
  • RSS News Feeds
  • Home
  • About
  • Technology
  • Products
  • Pipeline
  • Investors
  • Contact Us
  • News
  • Careers
  • Sitemap
  • Terms and Conditions
  • Privacy Policy
  • Patent Notification
Menu
  • Home
  • About
  • Technology
  • Products
  • Pipeline
  • Investors
  • Contact Us
  • News
  • Careers
  • Sitemap
  • Terms and Conditions
  • Privacy Policy
  • Patent Notification
EyePoint Logo

EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EYEPOINT, the EyePoint logo, DURASERT, YUTIQ, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals.
© EyePoint Pharmaceuticals. All rights reserved.

09/2021
US-EYP-2100003

Linkedin
Facebook
Twitter